|
Postmarket Trials, REMS Tied to Anemia Drug Approval
The FDA granted approval to Affymax’s and Takeda’s once-monthly anemia treatment Omontys, but has loaded the companies with postmarketing requirements, including two safety studies and a risk evaluation and mitigation strategy (REMS).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives